Health & Fitness
Health and Fitness
Health and Fitness 
Fri, September 3, 2010
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - WOPRAI
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
[ Fri, Sep 03rd 2010
] - Market Wire
Thu, September 2, 2010
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - WOPRAI
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - WOPRAI
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - WOPRAI
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
[ Thu, Sep 02nd 2010
] - Market Wire
ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September
WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each presentation can be accessed through the aInvestor Informationa section of the Companya™s website, [ www.immunogen.com ]; a replay of each presentation will be available for one week.
- 2010 Morgan Stanley Global Healthcare Unplugged Conference
8:00 a.m.EDT on September 13, 2010in New York, NY
Presenter: Daniel Junius, President and CEO
- Stifel Nicolaus 2010 Healthcare Conference
11:30 a.m.EDT on September 15, 2010in Boston, MA
Presenter: Gregory Perry, Senior Vice President and CFO - Bank of America Merrill Lynch Global Healthcare Conference 2010
1:00 p.m.BST (8:00 a.m. EDT) on September 16, 2010in London,England
Presenter: Daniel Junius, President and CEO - UBS Global Life Sciences Conference
12:00 p.m.EDT on September 20, 2010inNew York, NY
Presenter: Gregory Perry, Senior Vice President and CFO
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer cell-killing agents. The Companya™s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumor targets. Product candidates are in development through the Companya™s own product programs and through ImmunoGena™s collaborations with Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), and sanofi-aventis. The most advanced compound using ImmunoGena™s TAP technology, T-DM1, is in Phase III testing through the Companya™s collaboration with Genentech.